The CD52 Knockout HAP1 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population that disrupts the CD52 gene in the near-haploid HAP1 cell line. This loss-of-function model preserves the host cell background while removing CD52 expression, enabling dissection of CD52-dependent processes. The polyclonal format, generated by CRISPR/Cas9-mediated gene disruption, contains a diverse spectrum of edits, offering flexibility for pooled functional genomics and screening applications.
HAP1 is a near-haploid human chronic myeloid leukemia cell line derived from KBM-7, with adherent, fibroblast-like morphology and haploidy for most chromosomes. This genetic constitution simplifies the generation of complete gene knockouts and ensures unambiguous genotype?Cphenotype relationships. As a result, HAP1 is widely used in genetic screening, functional genomics, and cancer biology. Its hematopoietic lineage provides a relevant context for studying immune signaling molecules like CD52.
CD52 encodes a glycosylphosphatidylinositol (GPI)-anchored glycoprotein expressed on the surface of lymphocytes. The protein is embedded in lipid raft microdomains and interacts with the TCR complex, CD4, and CD8. Upon crosslinking by antibodies or cell-cell interactions, CD52 initiates signal transduction through Src family kinases, particularly Lck, leading to phosphorylation and activation of ZAP-70. Upstream inputs from TCR and BCR activation, as well as STAT signaling, converge on CD52, modulating lymphocyte activation, proliferation, and survival. The GPI-anchor biosynthesis pathway is essential for CD52 membrane expression and function.
In the HAP1 background, CD52 knockout enables the study of receptor-proximal signaling events without the complexity of primary immune cells. This model is particularly relevant for investigating mechanisms of resistance to alemtuzumab, a humanized anti-CD52 antibody used in treating chronic lymphocytic leukemia and multiple sclerosis. Additionally, it provides a platform to explore the role of CD52 in autoimmune disorders and lymphoproliferative diseases, leveraging the clean genetic environment of HAP1 to dissect signaling networks.
This cell population supports diverse experimental applications, including immunophenotyping by flow cytometry, expression analysis via Western blotting, apoptosis assays, and ADCC assays to evaluate therapeutic antibodies. The cells can also be employed in kinase activation profiling to monitor Lck and ZAP-70 signaling, and in pooled CRISPR screens to identify synthetic lethal partners. For further information or to discuss custom projects, please contact Ascent Research.
